Fc epsilon receptor II/CD23-positive lymphocytes in atopic dermatitis. I. The proportion of Fc epsilon RII+ lymphocytes correlates with the extent of skin lesion.
Cells expressing Fc receptors for IgE (Fc epsilon RII) were identified in the peripheral blood from patients with atopic dermatitis and with eczematous dermatitis, and normal non-atopic subjects by using monoclonal antibodies to human lymphocyte Fc epsilon RII, and to lymphoid cell-surface antigens by immunofluorescence staining. Based on the extent of the dermatitis patients were classified as severe (greater than 50% skin surface involved), moderate (50-10%) and mild (less than 10%). Patients with severe and moderate atopic dermatitis had 5.9% and 5.7% Fc epsilon RII+ peripheral blood mononuclear cells (PBMC), respectively, that were significantly higher than percentages in mild atopic dermatitis patients (2.6%), severe to moderate eczematous dermatitis patients (2.3%), mild eczematous dermatitis patients (2.2%) and normal individuals (1.7%)(0.05 greater than P). In severe and moderate atopic dermatitis patients, 10% of Fc epsilon RII+ PBMC were T cells that preferentially expressed CD8, and the remainder B cells and monocytes. Fc epsilon RII+ T cells comprised 1% of peripheral T cells, while half or more of peripheral B cells expressed Fc epsilon RII. In mild atopic dermatitis patients, eczematous dermatitis patients and normal subjects. Fc epsilon RII were expressed exclusively on 25-35% of peripheral B cells. Short-term treatment and long-term follow-up of atopic dermatitis patients revealed that changes in the skin condition were related closely to fluctuations in the proportion of Fc epsilon RII+ PBMC. Total serum IgE levels and atopic respiratory allergy did not influence the percentage of Fc epsilon RII+ PBMC. These findings suggest that the percentage of Fc epsilon RII+ PBMC reflects the extent of atopic dermatitis.
Department of Dermatology, Hamamatsu University School of Medicine, Japan.
M
M
Takigawa
T
T
Tamamori
D
D
Horiguchi
T
T
Sakamoto
M
M
Yamada
A
A
Yoshioka
K
K
Toda
S
S
Imamura
J
J
Yodoi
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000944:Antigens, Differentiation, B-Lymphocyte / Q000032:analysis*; D001249:Asthma / Q000276:immunology; D002648:Child; D003172:Complement C1 / Q000032:analysis / Q000187:drug effects; D003876:Dermatitis, Atopic / Q000188:drug therapy / Q000276:immunology*; D004485:Eczema / Q000276:immunology; D005260:Female; D005455:Fluorescent Antibody Technique; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D007073:Immunoglobulin E / Q000032:analysis; D008214:Lymphocytes / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011961:Receptors, Fc / Q000032:analysis* / Q000187:drug effects; D017455:Receptors, IgE; D012044:Regression Analysis; D012220:Rhinitis / Q000276:immunology
D000305:Adrenal Cortex Hormones; D000944:Antigens, Differentiation, B-Lymphocyte; D003172:Complement C1; D006634:Histamine H1 Antagonists; D011961:Receptors, Fc; D017455:Receptors, IgE; D007073:Immunoglobulin E